Objective-ADAMTS13 (A Disintegrin And Metalloprotease with Thrombospondin type 1 repeats, 13) cleaves von Willebrand factor (VWF), thereby inhibiting thrombus formation. Proteolytic cleavage relies on the amino-terminal (MDTCS) domains, but the role of the more distal carboxyl-terminal domains of ADAMTS13 is not fully understood.
V on Willebrand factor (VWF), an ultra large (UL) or large multimeric adhesion glycoprotein in blood, is primarily synthesized in endothelial cells, megakaryocytes, and platelets. 1 The newly synthesized VWF is stored in the Weibel-Palade bodies of endothelial cells or α-granules of platelets. ULVWF is released from these storage organelles on stimulation by epinephrine, histamine, thrombin, and inflammatory cytokines or toxins. [2] [3] [4] The newly released ULVWF forms string-like structures anchored on the cell surface, [2] [3] [4] which are hyperactive and recruit flowing platelets from circulation to the site of endothelial activation or injury. Cell-bound ULVWF strings are highly susceptible to proteolysis by plasma metalloprotease ADAMTS13. 2, 3 This proteolytic cleavage results in a VWF-free endothelial surface, preventing unwanted and excessive platelet adhesion/aggregation and thrombus formation after injury. However, VWF released into circulation remains large and therefore requires further processing by plasma ADAMTS13, 5 other leukocyte proteases, 6 and complement factor H. 7 An inability to cleave or process cell-bound ULVWF or circulating large VWF multimers into smaller ones results in a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP), 8, 9 which is characterized by severe thrombocytopenia and microangiopathic hemolytic anemia with various degrees of organ failure. 8, 9 Previous studies have demonstrated that the proteolytic cleavage of VWF by ADAMTS13 depends on the amino-terminal portion of ADAMTS13 (ie, MDTCS domains). [10] [11] [12] [13] [14] [15] [16] An extensive exosite interaction between the ADAMTS13-DTCS domains and the VWF-A2 domain 11, 17 seems to be necessary for productive VWF cleavage. A February 2014 mutation or deletion in the DTCS domains [18] [19] [20] or an autoantibody that targets the spacer domain or others 19, [21] [22] [23] [24] dramatically reduces or inhibits the ability of ADAMTS13 to cleave its VWF substrate. However, the role of more distal C-terminal domains of ADAMTS13, including the 2 to 8 TSP1 repeats and CUB domains, is little known.
Recently, Yeh et al have reported that the C-terminal TSP1 repeats and CUB domains of ADAMTS13 contain a cluster of surface-exposed free thiols (-SH). 25 Using biochemical assays, these investigators demonstrated that the free thiols on recombinant ADAMTS13 interact with those on cell-bound ULVWF or soluble VWF under flow. 25 However, the physiological relevance of such an interaction has not been fully established. We hypothesize that by interacting with the free thiols on VWF, the C-terminal domains of ADAMTS13 may have direct antithrombotic activity under pathophysiological conditions.
To test this hypothesis, we have developed a microfluidic flow assay and an intravital microscopic imaging technique to assess the role of ADAMTS13C-terminal domains and their surface free thiols. We demonstrate that a C-terminal ADAMTS13 fragment comprising either 2 to 8 TSP1 repeats and CUB domains (T2C) or 5 to 8 TSP1 repeats and CUB domains (T5C) inhibits platelet aggregation on a collagen-coated surface under arterial flow. Moreover, the C-terminal fragment of ADAMTS13 (T2C or T5C) reduces the formation and elongation of platelet-decorated ULVWF strings and the aggregation of platelets/leukocytes on the endothelial cell surface in mesenteric venules after oxidative injury. These inhibitory activities are nearly completely abolished after T2C or T5C is pretreated with the alkylating agent N-ethylmaleimide (NEM) that blocks its surface free thiols. Moreover, pretreatment of a full-length ADAMTS13 with NEM also reduces its ability by ≈50% to inhibit the formation of platelet-decorated ULVWF strings on endothelial cells. Together, these results indicate that the C-terminal domains of ADAMTS13 are of direct antithrombotic activity in a free-thiol-dependent manner, and these free thiols on the C-terminal domains of ADAMTS13 may contribute to overall antithrombotic activity of ADAMTS13 under (patho)physiologically relevant conditions.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Characterization of Recombinant ADAMTS13 and Its C-Terminal Fragments
Recombinant human full-length ADAMTS13 (rA13) and its C-terminal fragments (T2C and T5C; Figure 1A ) were expressed in stably transfected Chinese hamster ovarian cell line-s cell lines and purified to homogeneity with a combination of Q-fast flow anion exchange and Ni-chelating affinity chromatography. 15, 18 As shown in Figure 1B , rA13, T2C, and T5C were purified to >95% purity, revealed by an SDS-polyacrylamide gel with coomassie blue staining. The C-terminal domains of ADAMTS13 were shown in a previous study to contain multiple surface-exposed free thiols. 25 To confirm the presence of free thiols in our recombinant products, we performed labeling with N-ethylmaleimide (NEM). In these experiments, purified rA13, T2C, and T5C were incubated at 4°C with NEM (5 mmol/L) at pH 7.5. Under these conditions, NEM specifically reacts with the sulfhydryl (-SH) groups on free-cysteine residues without affecting preformed disulfide bonds and protein structure and functionality. In our control experiments, we found that the multimer distribution of NEM-treated VWF was not different from that of untreated VWF (data not shown). In addition, the NEM-labeled rA13 exhibited normal proteolytic activity in cleaving the FRETS-VWF73 peptide ( Figure 1C ) and multimeric VWF ( Figure 1D ) as compared with the untreated rA13.
The NEM-labeled rA13 and the C-terminal fragments were resolved on a 10% SDS-polyacrylamide gel and stained with coomassie blue. Specific bands were cut out from the gel and digested overnight with trypsin using a standard protocol established at the Penn Proteomic Core. The resulting peptides were identified by a Nano LC-tandem mass spectrometer. The massto-charge ratio (m/z) was determined for each peptide derived from the proteins with or without NEM modifications. The Table shows the identification of cysteine residues that were modified by NEM in the C-terminal domains of ADAMTS13. These included Cys710, Cys769, Cys799, Cys919, Cys933, Cys977, Cys1213, and Cys1275 in the C-terminal TSP1 repeats and CUB-1 domain of ADAMTS13. Occasionally, additional NEM-labeled cysteine residues were detected in the N-terminal MDTCS domains (not shown) if a full-length rA13 protein instead of C-terminal fragments of ADAMTS13 was used in the experiments. However, because of the low recovery of peptides in the N-terminal MDTCS domains, the exact number of free thiols in this region remains to be determined. Four other cysteine residues, including Cys710, Cys799, Cys919, and Cys977, found to be modified by NEM in the current study were not identified in the previous study. 25 One cysteine residue (Cys1192) that was identified to be a free thiol in the previous study was not determined in this study because of failure of recovering the peptide (Table) . Nevertheless, our results are largely in agreement with those reported previously, 25 independently confirming the presence of multiple free-cysteine residues that are clustered on the C-terminal TSP1 repeats and CUB domains of recombinant ADAMTS13 protein. 
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Development of a Microfluidic Flow Assay for Assessing Proteolytic and Nonproteolytic Activities of ADAMTS13 Under Flow
To assess the biological functions of ADAMTS13 under more physiologically relevant conditions, we established a microfluidic flow assay. In this assay, the microfluidic flow channels were coated with fibrillar collagen and perfused over with PPACK-anticoagulated whole blood from wild-type (WT) or Adamts13 -/-(KO) mice under various shear stresses. The percentage coverage of fluorescein-labeled platelets on the collagen surface with time was determined. We showed that in the absence of plasma ADAMTS13 (such as in KO mice), the percentage of surface coverage by fluorescent platelets increased dramatically as a function of increasing shear stresses (Figure 2A and 2B). In contrast, in the presence of physiological concentrations of ADAMTS13 (such as in WT mice), the percentage of platelet coverage on the collagen surface did not significantly increase (or even slightly decreased) as a function of increasing shear stresses (Figure 2A and 2B). For instance, at the highest shear stress (≈200 dyne/cm 2 ), the percentage of KO mouse platelets that adhered and aggregated on the collagen surface was ≈8-fold higher than that of WT mouse platelets (P<0.01; Figure 2B ). However, such a difference was not observed when blood was perfused at a relatively low arterial shear stress (20 dyne/cm 2 ; Figure 2B ). These results are highly consistent with those reported previously, [26] [27] [28] suggesting that mice lacking plasma ADAMTS13 activity are prothrombotic, particularly under pathological shear stresses. The prothrombotic phenotypes of KO mice may be caused by increased plasma levels of ULVWF and lack of antithrombotic ADAMTS13 protease. To further determine the role of plasma ADAMTS13 in the surface coverage of murine platelets on the collagen surface, we reconstituted PPACK-anticoagulated whole blood from KO mice with human rA13 at various concentrations (0, 12.5, 25, 50, and 100 nmol/L). After perfusion through collagen-coated microfluidic flow channels under ≈100 dyne/cm 2 , we found that the percentage of platelet coverage was inhibited by supplemented rA13 in a concentration-dependent manner ( Figure 2C ). For instance, in the presence of 12.5 nmol/L and 100 nmol/L of rA13, the percentage of platelet coverage at the end of 2-minute perfusion reduced by 30% and 80%, respectively, similar to that in WT mouse platelets ( Figure 2C) . Surprisingly, even in the presence of heat-inactivated rA13 (500 nmol/L), which exhibited no residual proteolytic activity toward FRETS-VWF73 ( Figure 2E ), the percentage of platelet coverage on the collagen surface was also significantly reduced ( Figure 2D ). These results suggest that the microfluidic flow assay is highly sensitive to assess both proteolytic and nonproteolytic activities of ADAMTS13.
Figure 1. Constructs and purified recombinant A Disintegrin
And Metalloprotease with Thrombospondin type 1 repeats, 13 (ADAMTS13) and its C-terminal fragments. A, Full-length human ADAMTS13 (rA13) comprises a signal peptide (S), a propeptide (P), a metalloprotease (M), a disintegrin domain (D), a cysteine rich (C), the first thrombospondin type 1 repeats (TSP1), and a spacer domain (S). The more distal C terminus contains 7 more TSP1 repeats (2-8) and 2 complement C1r/C1s, Uegf, bone morphogenic protein 1 (CUB) domains (C1-C2). The signal peptide and propeptide are cleaved ( ) on secretion, and a V5-His epitope is attached to the C-terminal end in each construct. In addition, a 3xFlag tag was added to the C-terminal fragments of ADAMTS13 after the leader sequence (Igk) was removed ( ) during secretion. T2C or T5C refers the construct consisting of 2 to 8 TSP1 repeats plus CUB domains or 5 to 8 TSP1 repeats plus CUB domains. B, SDS-polyacrylamide (10%) gel electrophoresis and coomassie blue staining determined the purity of recombinant ADAMTS13 (rA13), T2C, and T5C (≈5-10 μg of total protein/ lane). M in lane 1 is a prestained and broad range protein marker. C and D are the relative activity of recombinant ADAMTS13 (rA13) with or without N-ethylmaleimide (NEM) treatment in the proteolytic cleavage of FRETS-VWF73 peptide and multimeric VWF, respectively. 
Table. Identification of the Free Thiols by Nano LC-Tandem Mass Spectrometry in the C-Terminal Domains of ADAMTS13
C-Terminal Fragments of ADAMTS13 Are Capable of Inhibiting Platelet Adhesion and Aggregation on a Collagen Surface Under Flow
With the establishment of the microfluidic flow assay, we asked the question whether the C-terminal domains of ADAMTS13, in the absence of proteolytic activity, inhibit platelet adhesion/aggregation on a collagen surface under flow. PPACK-anticoagulated human or murine (KO) whole blood was incubated with increasing concentrations of a C-terminal fragment of ADAMTS13 (T2C or T5C) and then flown over soluble ( Figure 3A -F) or fibrillar ( Figure 3G -L) collagen-coated surface under arterial shear stresses. In either case, T2C or T5C inhibited the percentage of platelet coverage on the collagen surface in a concentration-dependent manner. For instance, in the presence of ≈500 to 1000 nmol/L of T2C ( Figure 3A and 3C) or T5C ( Figure 3D and 3F) , the percentages of human platelets adhered and aggregated on the soluble collagen surface at the end of 3-minute perfusion were reduced by ≈70% or ≈80% ( Figure 3C and 3F) , similar to the inhibitory effect of 10 nmol/L rA13 (not shown). Similar but slightly less inhibitory effects of T2C ( Figure 3G and 3I) and T5C ( Figure 3J and 3L) on the percentage of KO mouse platelet coverage on the fibrillar collagen surface under high shear (≈200 dyne/cm 2 ) were observed. These results demonstrate for the first time that the C-terminal domains of ADAMTS13 without a catalytic subunit are capable of inhibiting platelet adhesion/aggregation and thrombus formation under arterial shear stresses.
To determine whether the inhibitory activity of T2C or T5C on platelet adhesion and aggregation on the collagen surfaces depends on its surface free thiols, a purified T2C or T5C was pretreated with NEM, which blocks surface free thiols. As shown, reconstitution of PPACK-anticoagulated KO mouse whole blood with NEM-treated T2C ( Figure 3B and 3E) or T5C ( Figure 3H and 3K) at various concentrations (0, 100, 500, and 1000 nmol/L) had no significant inhibitory effect on the percentage of platelet coverage on the fibrillar collagen surface under the same conditions ( Figure 3C , 3F, 3I and 3L, red bars). Only at the highest concentration (1000 nmol/L) was the inhibitory activity of NEM-treated T5C on platelet adhesion/aggregation detected ( Figure 3L, red bar) . These results indicate that antithrombotic activity of the C-terminal domains of ADAMTS13 is mediated by their surface thiols.
Of interest, binding of rA13 and C-terminal fragments to immobilized type 1 collagen and VWF (as positive controls) was performed. As shown in Figure I in the online-only Data Supplement, rA13, T2C, and T5C bound to collagen with dissociation constants (K D ; S) of 257±87, 79±29, and 106±30 nmol/L, respectively. The K D (S) was 35-, 9-, and 18-fold higher than those of binding of rA13 (K D =8.2±1.6 nmol/L), T2C (K D =8.4±2.5 nmol/L), and T5C (K D =5.3±1.2 nmol/L) to immobilized VWF under the same conditions ( Figure I in the online-only Data Supplement). These results suggest that full-length ADAMTS13 and its C-terminal fragments can directly interact with collagen, but this low affinity binding is not expected to affect high affinity interaction between VWF and collagen.
To determine whether rA13 and C-terminal fragments affect platelet-collagen binding, we determined the platelet aggregation induced by type 1 collagen in the absence and in the presence of purified rA13, T2C, and T5C. Figure II in the online-only Data Supplement shows that in the presence of 10 nmol/L of rA13, 100 nmol/L of T2C, and 100 nmol/L of T5C, no inhibition of murine platelet aggregation was induced by type 1 collagen. These results indicate that the antithrombotic effect of rA13 and its C-terminal fragments is less likely to be mediated by direct interference with VWF-collagen or platelet-collagen interaction.
C-Terminal Fragments of ADAMTS13 Also Inhibit the Formation of ULVWF Strings and Platelet-Leukocyte Aggregates on Endothelial Cells In Vivo
To determine the specificity of the antithrombotic function of the C-terminal domains of ADAMTS13, the effects of T2C or T5C on the formation of platelet-decorated ULVWF strings and adhesion/aggregation of platelets/leukocytes on endothelial cells were determined in a murine model. In these experiments, a mesenteric venule from KO mice was injured by 7.5% FeCl 3 , and the area immediately downstream from the injury site was located and imaged under a fluorescent microscope. Platelet-decorated ULVWF strings and platelet/leukocyte accumulation were clearly visible in this location. In the absence of plasma ADAMTS13, such as in the KO mice, the formation of ULVWF strings on the endothelial cell surface is highly dynamic, with some strings formed and others disappeared with time. However, the average length of ULVWF strings was fairly constant during the recording time (~180 seconds; Figures 4A, 4B , and 5A, and Movie I in the online-only Data Supplement). An infusion of rA13 at its physiological concentration (10 nmol/L) resulted in a rapid and significant reduction of the average length of platelet-decorated ULVWF strings (Figures 4D, 5B, and 5J ) and the percentage of surface coverage by platelet/leukocyte aggregates on the endothelial cell surface (Figures 4D, 6B , and 6J and Movie II in the online-only Data Supplement). Interestingly, an infusion of T2C or T5C also significantly reduced the average length of platelet-decorated ULVWF strings (Figures 4 and 5 ) and the formation of platelet/leukocyte aggregates (Figures 4 and 6 ) in a concentration-dependent manner. For instance, after an infusion of 500 nmol/L of T2C and T5C, the average length of the ULVWF strings on endothelial cells was reduced by ≈50% and ≈40%, respectively (Figures 4 and 5 and Movie III in the online-only Data Supplement), whereas the percentage of surface coverage of platelet/leukocytes was reduced by ≈40% ( Figures 4 and 6 and Movie III in the online-only Data Supplement). This was less than the efficacy of 10 nmol/L of rA13 under the same conditions ( Figure 6J ). Nevertheless, our results demonstrate for the first time that the C-terminal noncatalytic domains of ADAMTS13 are capable of inhibiting ULVWF string formation and platelet/leukocyte accumulation on endothelium after injury.
To determine whether the inhibitory effect of T2C and T5C on ULVWF string formation and platelet/leukocyte accumulation is mediated by their surface free thiols, similar experiments were performed using the NEM-treated proteins. As shown, pretreatment of T2C or T5C with NEM completely abolished its ability to inhibit the formation of ULVWF strings (Figures 4 and 5 ) and platelet/leukocyte aggregates (Figures 4 and 6 ) on activated endothelium. Furthermore, pretreatment of rA13 with NEM resulted in an ≈40% reduction in inhibiting the ULVWF string formation (Figures 4 and 5) and an ≈60% reduction in attenuating the platelet and leukocyte aggregation (Figures 4 and 6 ) on endothelium. Together, these results suggest that the surface free thiols on the C-terminal domains of ADAMTS13 may contribute to the protease-independent antithrombotic activity of ADAMTS13 in vivo.
Discussion
Our present study demonstrates that the C-terminal domains of ADAMTS13 are capable of inhibiting thrombus formation under flow, independent of proteolytic activity. This novel function of the C terminus of ADAMTS13 has been demonstrated with 2 independent assay systems. First, a microfluidic assay demonstrates that C-terminal ADAMTS13 fragments (T2C and T5C) lacking the protease domain or heat-inactivated rA13 lacking proteolytic activity inhibits platelet adhesion/aggregation on a collagen surface under flow in a concentration-dependent manner (Figures 2 and 3) . Second, an intravital microscopic imaging analysis further shows that constructs T2C and T5C inhibit the in vivo formation of elongated platelet-decorated ULVWF strings and platelet/leukocyte aggregates on endothelium after oxidative injury in a dose-dependent manner (Figures 4-6) . The inhibitory activity of T2C or T5C on the platelet aggregation on the collagen surface or ULVWF string formation on the endothelial surface requires the presence of its surface free thiols because the treatment of T2C or T5C with NEM abolishes its antithrombotic activity in vitro ( Figure 3 ) and in vivo (Figures 4-6) .
However, the concentration of T2C or T5C required to achieve significant antithrombotic activity seems to be 20 to 40 times higher than that of plasma ADAMTS13 (2.5-5 nmol/L) in human and mice. This raises 2 interesting questions: (1) Is the thiol-dependent reductase activity important physiologically? (2) Can the species differences between human and murine VWF (or ADAMTS13) account for the high concentration required for an observable antithrombotic effect? NEM-treated rA13 exhibits an ≈50% reduction of its inhibitory activity on the formation of ULVWF strings ( Figure 5 ) and platelet/leukocyte aggregates ( Figure 6 ) on activated endothelium despite having normal proteolytic activity in vitro ( Figure 1C and 1D ), suggesting the importance of surface free thiols on ADAMTS13 in its overall antithrombotic function in vivo. Previous studies have demonstrated the low cleavage efficiency of mouse VWF by human ADAMTS13 or vice versa, 15, 29 supporting the notion that species differences between human and mouse VWF (or ADAMTS13) may account for the high concentrations of human recombinant ADAMTS13 and variants required for the inhibitory effects observed under our experimental conditions. It remains to be determined, however, how the free thiols in the C-terminal domains of ADAMTS13 exert their antithrombotic function under flow. Yeh et al 25 have shown that the free thiols clustered on the C-terminal TSP1 repeats of ADAMTS13 interact with the free thiols on VWF under shear. These investigators hypothesize that such interactions may prevent VWF-VWF lateral association, thereby reducing VWF adhesiveness. NEM-labeling coupled with mass spectrometry has allowed us to identify multiple free-cysteine residues in the TSP1 repeats and CUB domains of ADAMTS13 (Table) . Four free-cysteine residues (Cys710, Cys799, Cys919, and Cys977) identified in this study were not reported in the previous study. 25 This may be related to the repeated experiments and prolonged incubation of rA13 and C-terminal fragments with NEM in this study. A prolonged incubation may result in protein conformational changes that expose additional Dynamic changes in the surface coverage of platelet/leukocyte aggregates on endothelium before and after infusion of full-length human A Disintegrin And Metalloprotease with Thrombospondin type 1 repeats, 13 (ADAMTS13; rA13) and its C-terminal fragments. A-I, Dynamic changes in the percentage of surface coverage of platelet/leukocyte aggregates on endothelial cells after oxidative injury before and after infusion (↓) of PBS, rA13 (10 nmol/L), ADAMTS13 fragment consisting of 2 to 8 thrombospondin type 1 repeats plus complement C1r/C1s, Uegf, bone morphogenic protein 1 (CUB) domains (T2C; 10 and 500 nmol/L), and ADAMTS13 fragment consisting of 5 to 8 thrombospondin type 1 repeats plus CUB domains (T5C; 10 and 500 nmol/L) that were untreated or treated with N-ethylmaleimide (NEM) as indicated in each graph. The data are the mean±standard errors (SEM) from 3 mice (n=3) for each treatment. J summarizes the percentage changes (mean±SEM, n=3) in the surface coverage of platelet/leukocyte aggregates on endothelium after infusion of PBS, rA13 (10 nmol/L), T2C (10 and 500 nmol/L), and T5C (10 and 500 nmol/L) untreated (blue bars) or treated (red bars) with NEM. Statistical analysis was performed using ANOVA analysis. Stars in J indicate that the differences were statistically highly significant compared with PBS-control. February 2014 free-cysteine residues. More free-cysteine residues have been detected if a protein such as VWF is unfolded by a denaturing agent or under fluid shear stress. 25 There was a concern that prolonged incubation of rA13 or its C-terminal fragments with NEM may result in modification of additional residues (such as lysine), reduce the preformed disulfide bonds, and alter the protein structure and function. To rule out these possibilities, we examined all NEM-labeled peptides and did not find NEM modification on other residues besides the cysteine residues. Moreover, a control multimeric VWF treated with NEM under the same conditions did not result in alteration of its multimer pattern by agarose gel electrophoresis (data not shown). Finally, the proteolytic activity of NEM-treated rA13 was compared with that of untreated rA13 in cleaving FRETS-VWF73 and multimeric VWF, and it was found to be identical ( Figures 1C and 1D ). Together, these results indicate that NEM treatment under the conditions described did not significantly alter the recombinant ADAMTS13 proteins in such a way that would affect their overall functionality nonspecifically.
Another intriguing question was whether rA13 and its C-terminal domains bind collagen and block VWF-collagen or platelet-collagen interaction. To address this, we have performed microtiter plate-binding assays and collagen-induced platelet aggregation. As shown in Figure I in the online-only Data Supplement, rA13, T2C, and T5C bind to immobilized type 1 collagen, but such a low affinity binding does not seem to affect high affinity binding between VWF and collagen. Also, binding of rA13 and C-terminal domains does not seem to interfere with the interaction between collagen and platelet ( Figure II in the online-only Data Supplement). Together, these results indicate that antithrombotic activity of C-terminal fragments of ADAMTS13 is less likely to be mediated through its blockage of VWF-collagen or plateletcollagen interaction. In support of this, a previous study has demonstrated that under arterial shear (1700 s −1 ), platelets do not adhere and aggregate onto collagen surface in the absence of VWF. 30 Therefore, the VWF-ADAMTS13 axis plays a key role in platelet adhesion/aggregation on a collagen surface under arterial flow.
In conclusion, we demonstrate that the C-terminal ADAMTS13 fragments have direct antithrombotic activity under pathophysiological conditions. This antithrombotic activity is mediated by a disulfide bond reduction mechanism independent of proteolytic activity. These findings shed new light on the biology of ADAMTS13 in vivo and may provide novel insights into the mechanisms of TTP and other arterial thrombosis. Whether an isolated C-terminal ADAMTS13 fragment can be used as a therapeutic agent for TTP or other arterial thrombosis remains to be determined in a disease-specific animal model.
